☆ 4.1 Letter

Successful treatment of chronic severe alopecia areata with abrocitinib

AUSTRALASIAN JOURNAL OF DERMATOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Pharmacology & Pharmacy

Abrocitinib: First Approval

Emma D. Deeks et al.

Summary: Abrocitinib is an oral small-molecule inhibitor of JAK1 developed by Pfizer for moderate-to-severe atopic dermatitis, approved in the UK, Japan, and the EU, with regulatory applications under review in other countries. This marks the first approval for treating moderate-to-severe AD with this medication.

DRUGS (2021)

Add to Collection

Review Pharmacology & Pharmacy

JAK inhibition in the treatment of alopecia areata - a promising new dawn?

Fathima Ferial Ismail et al.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2020)

Add to Collection

Article Dermatology

The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata

Nekma Meah et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Eric L Simpson et al.

LANCET (2020)

Add to Collection

Article Dermatology

Treatment of alopecia areata: An Australian expert consensus statement

William C. Cranwel et al.

AUSTRALASIAN JOURNAL OF DERMATOLOGY (2019)

Add to Collection

© Peeref 2019-2024. All rights reserved.